Capital Impact Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-1,572
| Closed | -$179K | – | 136 |
|
|
2021
Q1 | $179K | Sell |
1,572
-24,010
| -94% | -$2.73M | 0.06% | 106 |
|
|
2020
Q4 | $3.54M | Sell |
25,582
-25,000
| -49% | -$3.46M | 0.87% | 47 |
|
|
2020
Q3 | $4.16M | Buy |
50,582
+20,000
| +65% | +$1.64M | 1.23% | 19 |
|
|
2020
Q2 | $2.39M | Sell |
30,582
-15,340
| -33% | -$1.2M | 0.8% | 57 |
|
|
2020
Q1 | $2.04M | Buy |
45,922
+1,789
| +4% | +$79.5K | 0.86% | 48 |
|
|
2019
Q4 | $1.89M | Hold |
44,133
| – | – | 0.66% | 86 |
|
|
2019
Q3 | $1.88M | Buy |
44,133
+7,968
| +22% | +$339K | 0.71% | 82 |
|
|
2019
Q2 | $2.24M | Sell |
36,165
-1,693
| -4% | -$105K | 0.82% | 33 |
|
|
2019
Q1 | $1.59M | Hold |
37,858
| – | – | 0.7% | 65 |
|
|
2018
Q4 | $1.59M | Buy |
37,858
+9,112
| +32% | +$381K | 0.68% | 68 |
|
|
2018
Q3 | $2.3M | Buy |
28,746
+1,672
| +6% | +$133K | 0.79% | 43 |
|
|
2018
Q2 | $2.06M | Sell |
27,074
-4,917
| -15% | -$374K | 0.76% | 44 |
|
|
2018
Q1 | $1.63M | Buy |
+31,991
| New | +$1.63M | 0.67% | 65 |
|